TTX-siLIN28B
/ TransCode, Massachusetts General Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 16, 2022
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
(GlobeNewswire)
- "Planned Milestones...Publication of preclinical results supporting therapeutic candidate, TTX-RIGA; Continuation of preclinical studies for therapeutic candidates TTX-RIGA, TTX-siPDL1, and TTX-siLIN28B....Research and development expense was $1.9 million in the first quarter of 2022, compared to $0.3 million in the first quarter of 2021."
Commercial • Preclinical • Oncology
1 to 1
Of
1
Go to page
1